Merck Serono Ventures joined venture capital firms Sunstone Capital, and BioMedPartners as new investors in Vaximm's latest $8m round.
Vaximm, a Switzerland-based developer of cancer vaccines, has raised SFr7.8m ($8m) from a consortium including Germany based drugs company Merck’s corporate venturing unit.
Merck Serono Ventures joined venture capital firms Sunstone Capital, and BioMedPartners as new investors in Vaximm, while the consortium was filled by BB Biotech Ventures, a Guernsey-based fund managed by Swiss investment bank Bellevue Group.
BB Biotech and Merck formed Vaximm as a joint venture spun out from the German company in 2008.
Klaus Breiner, chairman of Vaximm and …
